Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-18-010320

Options or other derivatives

  • Chief Executive Officer acquired 75,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Kulkarni Samarth Chief Executive Officer 2018-04-16 Grant or award · Stock Option (Right to Buy) −75,000 150,000 D
Loading xslF345X03/doc4.xml…